Vascular & Endovascular

Guerbet, a medical imaging company out of Villepinte, France, this week announced it received CE mark approval for its SeQure and DraKon devices, two microcatheters that facilitate the intra-arterial delivery of therapies and embolic materials to peripheral vessels.

Pennsylvania-based health company Orchestra BioMed has obtained FDA breakthrough device designation for its Virtue sirolimus-eluting balloon (SEB), according to a statement issued April 24.

The FDA’s Circulatory System Devices Panel of the Medical Devices Advisory Committee will meet in mid-June to discuss recent controversies and safety practices surrounding paclitaxel-coated and -eluting medical devices, according to a notice posted April 22.

The 71-year-old Framingham Heart Study has received $38 million from the National Heart, Lung, and Blood Institute to fund a new six-year study into the biology of aging.

The first study to test an experimental antiplatelet compound in humans found the therapy inhibited clot formation without increasing bleeding, suggesting it could avoid that dangerous side effect of other clot-preventing drugs.

Three physicians published an editorial in Stroke proposing that tertiary healthcare centers in cities be held to stricter standards for performing endovascular thrombectomy (EVT) than their rural counterparts.

Quantifying a patient’s blood-brain barrier dysfunction (BBBD) could help inform risk stratification and stroke prevention strategies following a transient ischemic attack (TIA), researchers reported in the May edition of Stroke.

When couples attended smoking cessation programs together, their odds of quitting were nearly six times higher than for people who attempted to kick the habit alone, according to preliminary research presented April 12 at EuroPrevent 2019.

The FDA has granted a breakthrough therapy designation to a novel reversal agent for ticagrelor called PB2452, PhaseBio Pharmaceuticals announced April 8.

Endovascular thrombectomy (EVT) significantly reduced the risk of 90-day mortality in patients with acute ischemic stroke compared to medical therapy alone, according to a meta-analysis of 10 randomized trials cited in the 2018 update to American stroke guidelines.

The actual cost of a heart attack or stroke to society is about double the direct medical costs when lost productivity for patients and caregivers is considered, according to a study published April 6 in the European Journal of Preventive Cardiology.

Left atrial appendage (LAA) closure with the Watchman device was associated with low rates of stroke and bleeding events in high-risk atrial fibrillation patients over a two-year follow-up period, according to a real-world analysis published April 3 in Circulation: Electrophysiology and Arrhythmia.